Cargando…

Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China

BACKGROUND: Isoniazid (INH) represents the cornerstone for the treatment of cases infected with Mycobacterium tuberculosis (MTB) strains. Several molecular mechanisms have been shown to be the major causes for INH resistance, while the dynamic change of mutations conferring INH resistance among MTB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huo, Fengmin, Lu, Jie, Zong, Zhaojing, Jing, Wei, Shi, Jin, Ma, Yifeng, Dong, Lingling, Zhao, Liping, Wang, Yufeng, Huang, Hairong, Pang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683513/ https://www.ncbi.nlm.nih.gov/pubmed/31382930 http://dx.doi.org/10.1186/s12879-019-4333-4

Ejemplares similares

Relapse Versus Reinfection of Recurrent Tuberculosis Patients in a National Tuberculosis Specialized Hospital in Beijing, China
por: Zong, Zhaojing, et al.
Publicado: (2018)

Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis
por: Zhang, Tingting, et al.
Publicado: (2019)

Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
por: Jing, Wei, et al.
Publicado: (2017)

Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis
por: Chen, Suting, et al.
Publicado: (2017)

Biological interpretation of the sporadic sputum smear-positive-culture-negative outcome for patients with tuberculosis undertaking treatments
por: Luo, Jingjing, et al.
Publicado: (2023)

Rapid Detection of Ethambutol-Resistant Mycobacterium tuberculosis from Sputum by High-Resolution Melting Analysis in Beijing, China
por: Wang, Jun, et al.
Publicado: (2020)

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China
por: Wang, Chenqian, et al.
Publicado: (2022)

Diagnostic Yield of Oral Swab Testing by TB-LAMP for Diagnosis of Pulmonary Tuberculosis
por: Song, Yanhua, et al.
Publicado: (2021)

Evaluation of a High-Intensity Green Fluorescent Protein Fluorophage Method for Drug- Resistance Diagnosis in Tuberculosis for Isoniazid, Rifampin, and Streptomycin
por: Yu, Xia, et al.
Publicado: (2016)

Distinguishing Relapse From Reinfection With Whole-Genome Sequencing in Recurrent Pulmonary Tuberculosis: A Retrospective Cohort Study in Beijing, China
por: Du, Jian, et al.
Publicado: (2021)

Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China, 2008–2017
por: Pang, Yu, et al.
Publicado: (2019)

Pulmonary Tuberculosis Caused by Mycobacterium bovis in China
por: Jiang, Guanglu, et al.
Publicado: (2015)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia
por: Binkhamis, Khalifa M., et al.
Publicado: (2021)

Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study
por: Kwak, Se Hyun, et al.
Publicado: (2020)

Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes
por: Wang, Wei, et al.
Publicado: (2022)

Genomic Stability over 9 Years of an Isoniazid Resistant Mycobacterium tuberculosis Outbreak Strain in Sweden
por: Sandegren, Linus, et al.
Publicado: (2011)

In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China
por: Yu, Xia, et al.
Publicado: (2021)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing
por: Huo, Fengmin, et al.
Publicado: (2020)

Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates
por: Muthaiah, Muthuraj, et al.
Publicado: (2017)

Isoniazid-Resistant Tuberculosis, Taiwan, 2000–2010
por: Lai, Chih-Cheng, et al.
Publicado: (2011)

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
por: Balcells, Maria Elvira, et al.
Publicado: (2006)

Isoniazid for preventing tuberculosis in HIV‐infected children
por: Zunza, Moleen, et al.
Publicado: (2017)

Isoniazid-induced liver disorder in the treatment of tuberculosis
por: Sivannan, Srinivasan, et al.
Publicado: (2018)

Dose of Isoniazid in Renal Disease for Treatment of Tuberculosis
por: Sarma, G. R. K.
Publicado: (2022)

Clinical Characteristics and Treatment Outcomes of Patients with Low- and High-Concentration Isoniazid-Monoresistant Tuberculosis
por: Wang, Tsai-Yu, et al.
Publicado: (2014)

The Mono-Prep system increases the detection rate of sputum smear microscopy for diagnosing tuberculosis
por: Wu, Jiannan, et al.
Publicado: (2018)

Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda
por: Kigozi, Edgar, et al.
Publicado: (2018)

Doubled Nontuberculous Mycobacteria Isolation as a Consequence of Changes in the Diagnosis Algorithm
por: Chen, Suting, et al.
Publicado: (2022)

The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study
por: Romanowski, Kamila, et al.
Publicado: (2019)

Optimization of SABRE for polarization of the tuberculosis drugs pyrazinamide and isoniazid
por: Zeng, Haifeng, et al.
Publicado: (2013)

Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis
por: Lentz, Fabian, et al.
Publicado: (2018)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas
por: Pienaar, Elsje, et al.
Publicado: (2018)

Electrospun Orodispersible Films of Isoniazid for Pediatric Tuberculosis Treatment
por: Chachlioutaki, Konstantina, et al.
Publicado: (2020)

Influence of sex on the exposure to isoniazid in patients with pulmonary tuberculosis
por: Rivera, Juan Gonzalo Bardalez, et al.
Publicado: (2023)

Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru
por: Villegas, Leonela, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3g8c0eipi3keta81s7pu5bu573